The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO 2021 | The mutagenic impact of melphalan in myeloma
Ola Landgren, MD, PhD, of Sylvester Comprehensive Cancer Center, University of Miami, FL, talks on the mutagenic impact of melphalan, a treatment for patients with multiple myeloma. Dr Landgren outlines the history of melphalan use in patients with myeloma and describes how high doses of melphalan have been shown to directly impact the mutational signature SBS-MM1, resulting in an increased mutational burden detected between diagnosis and relapse. In todays treatment landscape, Dr Landgren questions whether melphalan needs to be added to treatment regimens. This interview took place during the ninth annual meeting of the Society of Hematologic Oncology (SOHO 2021) congress.
